Abstract | BACKGROUND AND PURPOSE: EXPERIMENTAL APPROACH: KEY RESULTS: Systemic injection of cortistatin during the effector phase of the disease significantly reduced its prevalence and signs of heart hypertrophy and injury (decreased the levels of brain natriuretic peptide) and impaired myocardial inflammatory cell infiltration. This effect was accompanied by a reduction in self-antigen-specific T-cell responses in lymph nodes and in the levels of cardiomyogenic antibodies and inflammatory cytokines in serum and myocardium. Finally, we found a positive correlation between cardiac and systemic cortistatin levels and EAM severity. CONCLUSIONS AND IMPLICATIONS:
|
Authors | Virginia Delgado-Maroto, Clara P Falo, Irene Forte-Lago, Norma Adan, Maria Morell, Elena Maganto-Garcia, Gema Robledo, Francisco O'Valle, Andrew H Lichtman, Elena Gonzalez-Rey, Mario Delgado |
Journal | British journal of pharmacology
(Br J Pharmacol)
Vol. 174
Issue 3
Pg. 267-280
(02 2017)
ISSN: 1476-5381 [Electronic] England |
PMID | 27922195
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2016 The British Pharmacological Society. |
Chemical References |
- Cytokines
- Neuropeptides
- cortistatin
|
Topics |
- Animals
- Autoimmune Diseases
(drug therapy, immunology, physiopathology)
- Cardiomyopathy, Dilated
(drug therapy, immunology, physiopathology)
- Cytokines
(metabolism)
- Disease Models, Animal
- Female
- Inflammation
(drug therapy, immunology, physiopathology)
- Lymph Nodes
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Myocarditis
(drug therapy, immunology, physiopathology)
- Neuropeptides
(administration & dosage, pharmacology)
- Severity of Illness Index
- T-Lymphocytes
(immunology)
- Time Factors
|